Overall, the findings from this proof-of-concept study led us to consider that the AAbs as well as the immune monitoring of specific peripheral lymphocyte subsets should be investigated as potential biomarkers of autoimmunity and (potentially) treatment response in patients with NSCLC receiving PD-1/PD-L1 immune-checkpoint blockade. This evidence concerns the gene CD274 and non-small cell lung carcinoma.